99 related articles for article (PubMed ID: 31223029)
1. Effects of carfilzomib alone and in combination with cisplatin on the cell death in cisplatin-sensitive and cisplatin-resistant ovarian carcinoma cell lines.
Zarei S; Reza JZ; Jaliani HZ; Hajizadeh MR; Sargazi S; Hosseinian H
Bratisl Lek Listy; 2019; 120(6):468-475. PubMed ID: 31223029
[TBL] [Abstract][Full Text] [Related]
2. Millepachine showed novel antitumor effects in cisplatin-resistant human ovarian cancer through inhibiting drug efflux function of ATP-binding cassette transporters.
Wu W; Liu Y; Ye H; Li Z
Phytother Res; 2018 Dec; 32(12):2428-2435. PubMed ID: 30123958
[TBL] [Abstract][Full Text] [Related]
3. Malformin-A1 (MA1) Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis.
Abdullah N; Tamimi Y; Dobretsov S; Balushi NA; Alshekaili J; Al Balushi H; Al Kindi M; Hassan SI; Bahlani SA; Tsang BK; Burney IA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34199287
[TBL] [Abstract][Full Text] [Related]
4. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
5. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
[TBL] [Abstract][Full Text] [Related]
6. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
7. Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines.
Al Balushi N; Hassan SI; Abdullah N; Al Dhahli B; Al Bahlani S; Ahmed I; Tsang BK; Dobretsov S; Tamimi Y; Burney IA
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2661-2669. PubMed ID: 36037120
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
9. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
[TBL] [Abstract][Full Text] [Related]
11. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
Sharp SY; Smith V; Hobbs S; Kelland LR
Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
14. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
16. Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines.
Abdullah N; Al Balushi N; Hasan SI; Al Bahlani S; Dobretsov S; Tamimi Y; Burney IA
Sultan Qaboos Univ Med J; 2021 Nov; 21(4):632-634. PubMed ID: 34888085
[TBL] [Abstract][Full Text] [Related]
17. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers.
Long Q; Xiel Y; Huang Y; Wu Q; Zhang H; Xiong S; Liu Y; Chen L; Wei Y; Zhao X; Gong C
J Biomed Nanotechnol; 2013 Jun; 9(6):965-75. PubMed ID: 23858960
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cisplatin treatment given concurrently with pulsed irradiation in cisplatin sensitive and resistant human ovarian carcinoma cell lines.
Leblanc JM; Raaphorst P
Int J Radiat Biol; 2005 Jun; 81(6):429-35. PubMed ID: 16308913
[TBL] [Abstract][Full Text] [Related]
20. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
